Joan Puig de Dou
- Active in the pharmaceutical marketing for over 30 years
- President of CataloniaBIO&HealthTech
- CEO and Qualified Person at Kymos
- Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications.
Experience
Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&HealthTech to represent the Catalonian biotech industry nationally and internationally.
Expertise
Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader’s level of expertise. He publishes regularely on Kymos’ webpage, social media and in the specialized press.
Education
He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School’s Programa Diección General (PDG)
Want to know him better?
Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Scíentific de Barcelona.
Pharmaprogress – Bright lights are on the horizon
In 2023, Pharmaprogress will move into a more spacious, convenient, and state-of-the-art building in the Ancona area. Luca Gramaccioni, General Site Manager of Pharmaprogress, and his team are excited about having more room soon: "In (...) Read more
Dissolution testing for all dosage forms
In recent months, we unfortunately had to turn down repeated requests for dissolution tests for which we would have needed the Dissolution USP 4 CE 7smart device. This was neither satisfactory for our customers nor (...) Read more
Prolytic and Aeterna Zentaris – 20 years of improving human health together
For almost 20 years, Kymos’ German subsidiary Prolytic has accompanied Aeterna Zentaris in its development of pharmaceutical and diagnostic products. Katrin Dorfmeyer, Head of Chromatography, at Prolytic, and Dr. Michael Teifel, CSO at Aeterna Zentaris, (...) Read more
